Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 4, 2011, Pages 1272-1277

  Cantor, Jason R ^a   Yoo, Tae Hyeon ^a   Dixit, Aakanksha ^b   Iverson, Brent L ^c   Forsthuber, Thomas G ^b   Georgiou, George ^a,c  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Directed evolution; Protein engineering

Indexed keywords

ASPARAGINASE; EPITOPE; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CATALYSIS; CHILDHOOD LEUKEMIA; COMBINATORIAL CHEMISTRY; COMBINATORIAL SATURATION MUTAGENESIS; ENZYME DEIMMUNIZATION; ESCHERICHIA COLI; GENETIC SCREENING; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR EVOLUTION; MOUSE; NEUTRAL DRIFT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; T LYMPHOCYTE;

ANIMALS; ASPARAGINASE; CATALYTIC DOMAIN; COMPUTATIONAL BIOLOGY; DIRECTED MOLECULAR EVOLUTION; EPITOPES, T-LYMPHOCYTE; ESCHERICHIA COLI PROTEINS; FEMALE; FLOW CYTOMETRY; GENETIC DRIFT; HLA-DR ANTIGENS; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MALE; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MUTATION; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES;

ESCHERICHIA COLI; MUS MUSCULUS;

EID: 79952128822     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1014739108     Document Type: Article

References (55)

1. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 7:21-39.
2. Kim W, et al. (2004) Trends in enzyme therapy for phenylketonuria. Mol Ther 10:220-224. (Pubitemid 39117867)
3. Chohan S, Becker MA (2009) Update on emerging urate-lowering therapies. Curr Opin Rheumatol 21:143-149.
4. Ni Y, Schwaneberg U, Sun ZH (2008) Arginine deiminase, a potential anti-tumor drug. Cancer Lett 261:1-11.
5. Tan Y, Xu M, Hoffman RM (2010) Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells in vitro. Anticancer Res 30:1041-1046.
6. Cooney DA, Handschumacher RE (1970) L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol 10:421-440.
7. Haskell CM, Canellos GP, Cooney DA, Hansen HH (1970) Biocmical and pharmacologic effects of L-asparaginase in man. J Lab Clin Med 75:763-770.
8. Rytting M (2010) Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Th 10:833-839.
9. Schellekens H (2002) Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24:1720-1740.
10. Jevsevar S, Kunstelj M, Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5:113-128.
11. Armstrong JK, et al. (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110:103-111. (Pubitemid 46986423)
12. Sherman MR, Saifer MGP, Perez-Ruiz F (2008) PEG-uricase in the management Of treatment-resistant gout and hyperuricemia. Adv Drug Deliver Rev 60:59-68. (Pubitemid 350186186)
13. Yeung VP, et al. (2004) Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172:6658-6665. (Pubitemid 38669101)
14. Harding FA, et al. (2005) A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4:1791-1800. (Pubitemid 41685314)
15. Jones EY, Fugger L, Strominger JL, Siebold C (2006) MHC class II proteins and disease: A structural perspective. Nat Rev Immunol 6:271-282.
16. Wang P, et al. (2008) A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 4:e1000048.
17. Bander NH, et al. (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591-4601. (Pubitemid 46224061)
18. Macfarlane DJ, et al. (2006) Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99 mTc-DI-DD-3B6/22-80B3 Fab'. Eur J Nucl Med Mol I 33:648-656. (Pubitemid 43846755)
19. Holgate RG, Baker MP (2009) Circumventing immunogenicity in the development of therapeutic antibodies. IDrugs 12:233-237.
20. Benkovic SJ, Hammes-Schiffer S (2003) A perspective on enzyme catalysis. Science 301:1196-1202. (Pubitemid 37052200)
21. WarmerdamPA, et al. (2002) Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemostasis 87:666-673.
22. Amitai G, Gupta RD, Tawfik DS (2007) Latent evolutionary potentials under the neutral mutational drift of an enzyme. HFSP J 1:67-78.
23. Bloom JD, Romero PA, Lu Z, Arnold FH (2007) Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution. Biol Direct 2:17.
24. Bershtein S, Tawfik DS (2008) Advances in laboratory evolution of enzymes. Curr Opin Chem Biol 12:151-158.
25. Gupta RD, Tawfik DS (2008) Directed enzyme evolution via small and effective neutral drift libraries. Nat Methods 5:939-942.
26. Link AJ, Jeong KJ, Georgiou G (2007) Beyond toothpicks: New methods for isolating mutant bacteria. Nat Rev Microbiol 5:680-688. (Pubitemid 47278862)
27. Breaker RR, Banerji A, Joyce GF (1994) Continuous in-vitro evolution of bacteriophage RNA-polymerase promoters. Biochemistry 33:11980-11986. (Pubitemid 24328009)
28. Gates CM, Stemmer WP, Kaptein R, Schatz PJ (1996) Affinity selective isolation of ligands from peptide libraries through display on a lac repressor "headpiece dimer". J Mol Biol 255:373-386.
29. Yano T, Kagamiyama H (2001) Directed evolution of ampicillin-resistant activity from a functionally unrelated DNA fragment: A laboratory model of molecular evolution. Proc Natl Acad Sci USA 98:903-907. (Pubitemid 32121160)
30. Broome JD (1963) Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. II. Lymphoma 6C3HED cells cultured in a medium devoid of L-asparagine lose their susceptibility to the effects of guinea pig serum in vivo. J Exp Med 118:121-148.
31. Asselin BL, et al. (1989) In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 49:4363-4368.
32. Avramis VI, et al. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99:1986-1994. (Pubitemid 34525479)
33. Pui C-H, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178. (Pubitemid 43076714)
34. Horowitz B, et al. (1968) Asparagine synthetase activity of mouse leukemias. Science 160:533-535.
35. Ho DH, Whitecar JP, Jr, Luce JK, Frei E, 3rd (1970) L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow. Cancer Res 30:466-472.
36. Capizzi RL, et al. (1971) L-asparaginase: Clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 74:893-901.
37. Story MD, Voehringer DW, Stephens LC, Meyn RE (1993) L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 32:129-133. (Pubitemid 23131932)
38. Ueno T, et al. (1997) Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 11:1858-1861. (Pubitemid 27485130)
39. Zeidan A, Wang ES, Wetzler M (2009) Pegasparaginase: Where do we stand? Expert Opin Biol Th 9:111-119.
40. Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 1:241-254.
41. Duval M, et al. (2002) Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 99:2734-2739. (Pubitemid 34525359)
42. Derst C, Henseling J, Röhm KH (2000) Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci 9:2009-2017.
43. Asselin BL, et al. (1991) Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 51:6568-6573.
44. Dorak MT, et al. (1999) Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood 94:694-700. (Pubitemid 29323883)
45. Southwood S, et al. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363-3373. (Pubitemid 28164729)
46. Stecher AL, de Deus PM, Polikarpov I, Abrahão-Neto J (1999) Stability of L-asparaginase: An enzyme used in leukemia treatment. Pharm Acta Helv 74:1-9. (Pubitemid 30035397)
47. Huang J, et al. (2010) The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature 464:932-936.
48. Jensen PE (2007) Recent advances in antigen processing and presentation. Nat Immunol 8:1041-1048.
49. McHeyzer-Williams LJ, McHeyzer-Williams MG (2005) Antigen-specific memory B cell development. Annu Rev Immunol 23:487-513. (Pubitemid 40563178)
50. Stoop AA, Craik CS (2003) Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat Biotechnol 21:1063-1068. (Pubitemid 37064736)
51. Chen JC, Viollier PH, Shapiro L (2005) A membrane metalloprotease participates in the sequential degradation of a Caulobacter polarity determinant. Mol Microbiol 55:1085-1103. (Pubitemid 40299179)
52. Link AJ, Skretas G, Strauch EM, Chari NS, Georgiou G (2008) Efficient production of membrane-integrated and detergent-soluble G protein-coupled receptors in Escherichia coli. Protein Sci 17:1857-1863.
53. Yoo TH, Link AJ, Tirrell DA (2007) Evolution of a fluorinated green fluorescent protein. Proc Natl Acad Sci USA 104:13887-13890. (Pubitemid 350003306)
54. Ito K, et al. (1996) HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 183:2635-2644. (Pubitemid 26192372)
55. DeLano DW (2002) The PyMol Graphics System (DeLano Scientific, Palo Alto, CA).